Kevzara FDA Approval: Pharmacology and Rheumatoid Arthritis
This paper examines Kevzara (sarilumab), approved by the U.S. Food and Drug Administration on May 22, 2017, for the treatment of moderate to severe active rheumatoid arthritis in adults. The paper describes Kevzara's pharmacodynamic and pharmacokinetic properties as an interleukin-6 (IL-6) receptor antagonist, provides an overview of the rheumatoid arthritis disease state, and compares Kevzara to conventional therapies such as corticosteroids and nonsteroidal anti-inflammatory drugs. Potential risks and monitoring parameters are identified, including the screening for latent tuberculosis and vigilance for opportunistic infections. The paper concludes with a clinical recommendation that acknowledges the drug's promise while noting limitations in racial diversity among trial subjects.
- Introduction: FDA approval context and paper scope
- Kevzara: Description, Pharmacodynamics, and Pharmacokinetics: IL-6 antagonist mechanism and administration details
- Overview of the Rheumatoid Arthritis Disease State: RA symptoms, prevalence, and aging demographics
- How Kevzara Differs from Currently Available Therapies: Subcutaneous dosing vs. daily oral treatments
- Potential Risks and Monitoring Parameters: Infections, blood counts, and required monitoring
- Clinical Recommendation: Kevzara or Existing Alternatives?: Prescribing rationale and racial diversity caveat
- Conclusion: Summary of findings and clinical takeaways
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Follows a clear, logical structure that moves from drug description to disease context, comparative analysis, risk assessment, and clinical recommendation — mirroring real-world prescribing decision frameworks.
- Integrates FDA prescribing information alongside peer-reviewed sources, demonstrating appropriate use of both regulatory and academic evidence.
- Concludes the clinical recommendation section with a meaningful caveat about racial diversity in drug trials, showing critical thinking beyond surface-level approval endorsement.
Key academic technique demonstrated
The paper effectively uses direct quotation from a peer-reviewed source to anchor a pharmacological claim (the efficacy of IL-6 receptor antagonists), then supports it with FDA documentation. This layering of evidence — combining clinical trial snapshots, prescribing information, and journal articles — is a strong model for pharmacy and health sciences writing.
Structure breakdown
The paper is organized into seven sections: an introduction establishing clinical context and scope; a pharmacology section covering mechanism of action and administration; a disease-state overview with epidemiological data; a comparative section contrasting Kevzara with conventional treatments; a detailed risk and monitoring section using a bulleted list for clarity; a short but substantive prescribing recommendation with a racial equity caveat; and a summary conclusion tying all threads together.
Introduction
The exhaustive and lengthy approval process used by the U.S. Food and Drug Administration (FDA) means that when new drugs are released, they are considered sufficiently safe for human use as directed by physicians. This approval process, however, also means that relatively few new drugs are approved each year, including Kevzara, which is used to treat adult rheumatoid arthritis and was approved for release on May 22, 2017 (Novel drug approvals, 2017). Given the rapid increase in the elderly demographic in the U.S. in recent years — a trend projected to continue well into the 21st century (Poterba, 2016) — novel treatments for adult rheumatoid arthritis represent important and timely advances in drug therapy.
This paper provides a description of Kevzara, including its pharmacodynamic and pharmacokinetic properties, as well as an overview of the rheumatoid arthritis disease state for which it is used. In addition, a description of what distinguishes this drug from other currently available therapies is followed by a discussion of the potential risks associated with this agent and any monitoring parameters that are necessary. Finally, an analysis of whether this author would personally prescribe Kevzara or rely on currently available alternatives is followed by a summary of the research and important findings in the conclusion.
References
Drug trials snapshot. (2017). U.S. Food & Drug Administration. Retrieved from
Harris, E. D. (2009, September). The changing dimensions of rheumatoid arthritis and its treatment. Bulletin of the World Health Organization, 81(9), 631.
Hennigan, S. & Kavanaugh, A. (2008, August). Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 4(4), 767–775.
Highlights of prescribing information. (2017). U.S. Food & Drug Administration. Retrieved from
Novel drug approvals. (2017). U.S. Food & Drug Administration. Retrieved from
Overview of rheumatoid arthritis. (2017). National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from
Poterba, J. (2016, January). Economic implications of demographic change. Business Economics, 51(1), 3–5.
Rheumatoid arthritis in depth. (2017). National Center for Complementary and Integrative Health. Retrieved from
Rheumatoid arthritis statistics. (2017). Health Union. Retrieved from https://rheumatoidarthritis.net/what-is-ra/ra-statistics/.
Create your account
Always verify citation format against your institution’s current style guide requirements.